Ultrasounds – Risks, Benefits, and Ethical Considerations - BirthWorks International
Years ago, X-ray was the diagnostic procedure of choice in pregnancy but today we understand more about the harmful effects of radiation so ultrasound is used
Safety of Ultrasound Exposure: Knowledge, Attitudes, and Practices of Australasian Sonographers - Monique Moderiano, Maureen McEvoy, Jessie Childs, Adrian Esterman, 2018
Introduction: While perceived as safe, diagnostic ultrasound has the potential to cause biological effects on the body tissues. The aim of this study was to eva...
Grok is a free AI assistant designed by xAI to maximize truth and objectivity. Grok offers real-time search, image generation, trend analysis, and more.
Brain Health: Defending Against Modern Threats - Grok
Grok is a free AI assistant designed by xAI to maximize truth and objectivity. Grok offers real-time search, image generation, trend analysis, and more.
Randomized, waitlist-controlled trial of Cordyceps sinensis mycelium culture extract (Cs4) for long COVID patients in Hong Kong – ScienceOpen
We assessed
Cordyceps sinensis mycelium culture extract (Cs4) for alleviating long COVID symptoms. In this randomized
trial 110 participants were assigned to receive Cs4 (55 participants) or were waitlisted
(55 participants) for 12 weeks. The primary outcome was the change in long COVID symptom
severity at 12 weeks, as measured by the modified COVID-19 Yorkshire Rehabilitation
Scale. The secondary outcomes included changes in the Brief Fatigue Inventory Form,
Insomnia Severity Index, Hospital Anxiety and Depression Scale, St. George’s Respiratory
Questionnaire, and the Short Form 12 health survey at 12 weeks. Participants receiving
Cs4 showed improvement in long COVID symptoms compared to the waitlist control group
(MD, −10.1; 95% CI, −14.1 to −6.1;
P < 0.001) at 12 weeks. Cs4 recipients also experienced improvement in fatigue (MD,
−8.1; 95% CI, −14.2 to −2.0;
P = 0.011), insomnia (MD, −2.9; 95% CI, −4.6 to −1.2;
P = 0.001), and respiratory symptoms (MD, −6.3; 95% CI, −11.4 to −1.2;
P = 0.018). Cs4 also improved the quality of life (physical component MD, 7.0; 95%
CI, 4.2–9.8;
P < 0.001; mental component MD, 6.8; 95% CI, 2.9–10.7;
P < 0.001). No severe adverse events were reported. Cs4 may be a beneficial treatment
for patients with long COVID symptoms.